Formulation and Evaluation of Baclofen Floating Tablets

The present study was carried out with an objective of formulation and evaluation of floating tablets of baclofen for prolongation of gastric residence time with a view to deliver the drug at controlled manner in gastrointestinal tract and consequently into systemic circulation. Baclofen, a centrally acting skeletal muscle relaxant, is indicated in the long-term treatment of spasticity resulting for multiple sclerosis and spinal cord injuries. Therefore baclofen floating tablets were prepared by direct compression method using 3 grades of Eudragit (Eudragit L100, Eudragit S100, and Eudragit RSPO). Fourier transform Infrared spectroscopy confirmed the absence of any drug/polymers/excipient interactions. The prepared floating tablets were evaluated for hardness, weight variation, thickness, friability, drug content uniformity, total floating time, water uptake (swelling index) and in-vitro dissolution studies. Among the 12 formulations F3 showed drug release 98.37% in pH 1.2 dissolution medium. All the formulations showed drug content ranging from 80.93 to 98.37%. Drug release rate kinetics studies shown that drug release follows Higuchi mechanism.